Company Overview
About Outpace Bio
Outpace Bio is a clinical-stage biotechnology company headquartered in Seattle, Washington, founded to address one of the most significant unmet needs in oncology: creating effective cell therapies for solid tumors. While CAR-T cell therapies have transformed treatment of blood cancers, they have largely failed against solid tumors due to the immunosuppressive tumor microenvironment, T-cell exhaustion, and tumor heterogeneity. Outpace Bio applies AI-powered protein design and synthetic biology to engineer novel cellular logic circuits — custom genetic programs embedded in therapeutic T cells — that allow the cells to sense the tumor environment and respond adaptively rather than becoming exhausted or suppressed.
Business Model & Competitive Advantage
The company's platform is built on genetic "circuit" technology: engineered T cells that carry synthetic regulatory programs controlling their activation, persistence, and function based on environmental signals within the tumor. This approach, inspired by computational systems biology, allows Outpace to design cells that behave more like intelligent agents — capable of sustained activity in hostile environments — than conventional engineered T cells. Outpace Bio raised a $109M Series B in 2024, with investors including Andreessen Horowitz Bio, Arch Venture Partners, and other leading life sciences funds. The company was founded by researchers and executives with backgrounds in CAR-T therapy development and computational protein engineering.
Competitive Landscape 2025–2026
Outpace Bio operates in the advanced cell therapy sector alongside companies like Lyell Immunopharma, Tmunity (acquired by Kite/Gilead), A2 Biotherapeutics, and Senti Biosciences — all working to crack the solid tumor barrier for cell therapies. Its differentiation lies in the combination of AI-assisted protein design for novel therapeutic circuit components and its systems biology-driven approach to cell programming. The company's pipeline targets multiple solid tumor indications including colorectal, ovarian, and lung cancers.
Key Differentiators
Emerging Innovator
Outpace Bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Outpace Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Outpace Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Outpace Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Outpace Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →